# Trial of eRapa in Prostate Cancer Patients

> **NCT03618355** · PHASE1 · COMPLETED · sponsor: **Rapamycin Holdings, Inc. dba Emtora Biosciences** · enrollment: 15 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** eRapa (encapsulated rapamycin)

## Key facts

- **NCT ID:** NCT03618355
- **Lead sponsor:** Rapamycin Holdings, Inc. dba Emtora Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-28
- **Primary completion:** 2019-12-02
- **Final completion:** 2019-12-02
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03618355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03618355, "Trial of eRapa in Prostate Cancer Patients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03618355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*